Bismuth-213 and actinium-225 - generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes

Current Radiopharmaceuticals

Volumn 5, Issue 3, 2012, Pages 221-227

  Morgenstern, Alfred ^a   Bruchertseifer, Frank ^a   Apostolidis, Christos ^a  

^a JOINT RESEARCH CENTRE   (Italy)

Author keywords

Actinium 225; Alpha emitter; Bismuth 213; Clinical studies; Preclinical; Targeted alpha therapy

Indexed keywords

ACTINIUM 225; BISMUTH 213; LEAD; LINTUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9 2 27; MONOCLONAL ANTIBODY HUM195; POLONIUM; RITUXIMAB; SUBSTANCE P; TITANIUM; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ALPHA RADIATION; ARTERY CATHETER; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CHEMICAL PROCEDURES; CHROMATOGRAPHY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DOSIMETRY; ELECTRON; ENDOCRINE DISEASE; GLIOMA; HALF LIFE TIME; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKEMIA; LIVER DYSFUNCTION; LIVER METASTASIS; LYMPHOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; NEPHRITIS; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NONHUMAN; PHYSICAL ACTIVITY; PILOT STUDY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOISOTOPE DECAY; REVIEW; SEPSIS;

EID: 84863557811     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011205030221     Document Type: Review

References (54)

1. Sgouros, G.; Roeske, J.C.; McDevitt, M.R.; Palm, S.; Allen, B.J.; Fisher, D.R.; Brill, A.B.; Song, H.; Howell, R.W.; Akabani G; SNM MIRD Committee, Bolch, W.E.; Brill, A.B.; Fisher, D.R.; Howell, R.W.; Meredith, R.F.; Sgouros, G.; Wessels, B.W.; Zanzonico, P.B. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J. Nucl. Med., 2010, 51(2), 311-328.
2. Barendsen, G.W. Modification of radiation damage by fractionation of dose anoxia + chemical protectors in relation to LET. Ann. N. Y. Acad. Sci., 1964, 114(A1), 96-114.
3. Barendsen, G.W.; Koot, C.J.; van Kerson, G.R.; Bewley, D.K.; Field, S.B.; Parnell, C.J. The effect of oxygen on the impairment of the proliferative capacity of human cells in culture by ionizing radiations of different LET. Int. J. Radiat. Biol., 1966, 10, 317-327.
4. Wulbrand, C.; Seidl, C.; Gärtner, F.; Terjung, B.; Morgenstern, A.; Apostolidis, C.; Schwaiger, M.; Sebnekowitsch-Schmidtke, R. Die zytotoxische Wirkung von Alpha-Strahlung ist im Gegensatz zur Wirkung von Photonenstrahlung unabhängig vom Oxygenierungsgrad der Zellen. Nuklearmedizin, 2011, 50(2), A70.
5. 213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res., 2007, 67(5), 1950-1958.
6. 213Bi. Curr. Radiopharm., 2011, 4, 295-30543.
7. Jurcic, J.G.; Larson, S.M.; Sgouros, G.; McDevitt, M.R.; Finn, R.D.; Divgi, C.R.; Ballangrud, A.M.; Hamacher, K.A.; Ma, D.; Humm, J.L.; Brechbiel, M.W.; Molinet, R.; Scheinberg, D.A. Targeted alpha particle immunotherapy for myeloid leukemia. Blood, 2002, 100(4), 1233-1239.
8. Rosenblat, T.L.; McDevitt, M.R.; Mulford, D.A.; Pandit-Taskar, N.; Divgi, C.R.; Panageas, K.S.; Heaney, M.L.; Chanel, S.; Morgenstern, A.; Sgouros, G.; Larson, S.M.; Scheinberg, D.A.; Jurcic, J.G. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin. Cancer Res., 2010, 16(21), 5303-5311.
9. th Alpha-Immunotherapy Symposium, Düsseldorf, Germany, June 28-29, 2004.
10. Morgenstern, A., Ed.; Institute for Transuranium Elements: Karlsruhe, Germany, 2004; p. 11. http://itu.jrc.ec.europa.eu/index.php?id=205
11. Allen, B.J.; Raja, C.; Rizvi, S.; Li, Y.; Tsui, W.; Graham, P.; Thompson, J.F.; Reisfeld, R.A.; Kearsley, J.; Morgenstern, A.; Apostolidis, C. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther., 2005, 4(12), 1318-1324.
12. Raja, C.; Graham, P.; Abbas Rizvi, S.M.; Song, E.; Goldsmith, H.; Thompson, J.; Bosserhoff, A.; Morgenstern, A.; Apostolidis, C.; Kearsley, J.; Reisfeld, R.A.; Allen, B.J. Interim analysis of toxicity and response in Phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther., 2007, 6(6), 846-852.
13. Allen, B.J.; Singla, A.A.; Abbas Rizvi, S.M.; Graham, P.; Bruchertseifer, F.; Apostolidis, C.; Morgenstern, A. Analysis of patient survival in a Phase I trial of systemic targeted β-therapy for metastatic melanoma. Immunotherapy, 2011, 3(9), 1041-50.
14. Kneifel, S.; Cordier, D.; Good, S.; Ionescu, M.C.; Ghaffari, A.; Hofer, S.; Kretzschmar, M.; Tolnay, M.; Apostolidis, C.; Waser, B.; Arnold, M.; Mueller-Brand, J.; Maecke, H.R.; Reubi, J.C.; Merlo, A. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin. Cancer Res., 2006, 12(12), 3843-3850.
15. 213)Bi-DOTA-[Thi(8), Met(O(2) (11)]-substance P: a pilot trial. Eur. J. Nucl. Med. Mol. Imaging. 2010, 37(7), 1335-1344.
16. 213Bi-DOTATOC in GEP-NET patients refractory to beta-emitters. Abstracts of the Annual Meeting of the European Association of Nuclear Medicine, October 15-19, 2011, Birmingham, UK. Eur. J. Nucl. Med. Mol. Imaging. 2011, 38(Suppl 2), S80-85.
17. th Symposium on Targeted Alpha Therapy, Berlin, Germany, July 17-19, 2011; Morgenstern, A., Ed.; Institute for Transuranium Elements: Karlsruhe, Germany, 2011.
18. Nucleonica-Web driven nuclear science. European Commission, Joint Research Centre, Institute for Transuranium Elements, 2007. http://www.nucleonica.net/Index.aspx
19. Apostolidis, C.; Molinet, R.; Rasmussen, G.; Morgenstern, A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal. Chem., 2005, 77, 6288-6291.
20. Zielinska, B.; Apostolidis, C.; Bruchertseifer, F.; Morgenstern, A. An Improved Method for the Production of Ac-225/Bi-213 from Th-229 for Targeted Alpha Therapy. Solvent Extr. Ion. Exch., 2007, 25(3), 339-349.
21. Boll, R.A.; Malkemus, D.; Mirzadeh, S. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl. Rad. Isotop., 2005, 62, 667-679.
22. th Symposium on Alpha-Emitting Radionuclides in Therapy. Toronto, Canada, June 13-17, 2009.
23. Mirzadeh, S. Generator-produced alpha-emitters. Appl. Rad. Isotop., 1998, 49(4), 345-349.
24. Apostolidis, C.; Molinet, R.; McGinley, J.; Abbas, K.; Möllenbeck, J.; Morgenstern, A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl. Rad. Isotop., 2005, 62(3), 383-387.
25. Abbas, K.; Apostolidis, C.; Janssens, W.; Stamm, H.; Nikula, T.; Carlos-Marquez, R. Method for producing actinium-225. EP1455364, 2004.
26. th Alpha-Immunotherapy Symposium, Düsseldorf, Germany, June 28-29, 2004; Morgenstern, A., Ed.; Institute for Transuranium Elements: Karlsruhe, Germany, 2004; p. 11. http://itu.jrc.ec.europa.eu/index.php?id=205
27. Melville, G.; Meriarty, H.; Metcalfe, P.; Knittel T.; Allen, B.J. Production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226. Appl. Radiat. Isot., 2007, 65(9), 1014-1022.
28. 223Ra by irradiation of Th with accelerated protons. Radiochemistry, 2011, 53(1), 73-80.
29. th Symposium on Targeted Alpha Therapy, Berlin, Germany, July 17-19, 2011; Morgenstern, A., Ed.; Institute for Transuranium Elements: Karlsruhe, Germany, 2011.
30. th Symposium on Targeted Alpha Therapy, Berlin, Germany, July 17-19, 2011; Morgenstern, A., Ed.; Institute for Transuranium Elements: Karlsruhe, Germany, 2011.
31. Pippin, C.G.; Gansow, O.A.; Brechbiel, M.W.; Koch, L.; Molinet, R.; Van Geel, J.; Apostolidis, C.; Geerlings, M.W.; Scheinberg, D.A. Chemists View of Imaging Centers; Emran, A. M., Ed.; Plenum Press: New York, 1995; p 315.
32. 213Bi for alpha-particle-mediated radioimmunotherapy. J. Labelled Compd. Radiopharm., 1997, 40, 341.
33. 213Bi generator system for therapeutic clinical applications: construction and operation. Appl. Radiat. Isot., 1999, 50(5), 895-904.
34. Institute for Transuranium Elements, Annual Report 2006. ISBN 978-92-79-05001-5 http://itu.jrc.ec.europa.eu/uploads/media/Annu al_Report__2006.pdf
35. 225Ac. Radiochim. Acta 1997, 79, 141-144.
36. 213Bi for Repeated Production of Short-Lived β-Emitting Radionuclides. Radiochemistry, 2009, 51(2), 169-174.
37. Bray, L.A.; Tingey, J.M.; DesChane; J.R.; Egorov, O.B.; Tenforde, T.S.; Wilbur D. S; Hamlin, D.K.; Pathare. P.M.; Development of a Unique Bismuth (Bi-213) Automated Generator for Use in Cancer Therapy. Ind. Eng. Chem. Res., 2000, 39(9), 3189-3194.
38. McAlister D.R.; Horwitz E.P. Automated two column generator systems for medical radionuclides. Appl. Radiat. Isot., 2009, 67(11), 1985-1991.
39. 213Bi generator: development of new methods, quantitative characterization, and implications for clinical use. Appl. Radiat. Isot., 2001, 55(5), 667-678.
40. Spivakov, B.Y.; Stoyanov, E.S.; Gribov, L.A.; Zolotov, Y.A. Raman laser spectroscopic studies of bismuth(III) halide complexes in aqueous solutions. J. Inorg. Nucl. Chem., 1979, 41, 453-455.
41. McDevitt, M.R.; Ma, D.; Lai, L.T.; Simon, J.; Borchardt, P.; Frank, R.K.; Wu, K.; Pellegrini, V.; Curcio, M.J.; Miederer, M.; Bander, N.H.; Scheinberg, D.A. Tumor therapy with targeted atomic nanogenerators. Science, 2001, 294(5546), 1537-1540.
42. Miederer, M,; Scheinberg, D.A.; McDevitt, M.R. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev. 2008, 60(12), 1371-1382.
43. 213Bi-anti-EGFR-MAb defeats human bladder carcinoma in xenografted nude mice. J. Nucl. Med., 2009, 50(10), 1700-1708.
44. Park, S.I.; Shenoi, J.; Pagel, J.M.; Hamlin, D.K.; Wilbur, D.S.; Orgun, N.; Kenoyer, A.L.; Frayo, S.; Axtman, A.; Bäck, T.; Lin, Y.; Fisher, D.R.; Gopal, A.K.; Green, D.J.; Press, O.W. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood, 2010, 116(20), 4231-4239.
45. 177Lu-DOTA-PESIN). Cancer Res. 2011, 71(3), 1009-1018.
46. Song, H.; Shahverdi, K.; Huso, D.L.; Wang, Y.; Fox, J.J.; Hobbs, R.F.; Gimi, B.; Gabrielson, K.L.; Pomper, M.G.; Tsui, B.M.; Bhujwalla, Z.; Reilly, R.T.; Sgouros, G. An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer. Clin. Cancer Res., 2008, 14(19), 6116-6124.
47. 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res., 2008, 68(10), 3873-3880.
48. 90Y. Cancer Res., 2009, 69(23), 8941-8948.
49. 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res., 2010, 70(17), 6815-6823.
50. Pool, S.E.; Krenning, E.P.; Koning, G.A.; van Eijck, C.H.; Teunissen, J.J.; Kam, B.; Valkema, R.; Kwekkeboom, D.J.; de Jong, M. Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy. Semin. Nucl. Med., 2010, 40(3), 209-218.
51. 3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model. Clin. Cancer Res., 2006, 12(3), 897-903.
52. 177Lu in human pancreatic adenocarcinoma cells. Nucl. Med. Biol., 2007, 34(2), 185-193.
53. Drecoll, E.; Gaertner, F.C.; Miederer, M.; Blechert, B.; Vallon, M.; Müller, J.M.; Alke, A.; Seidl, C.; Bruchertseifer, F.; Morgenstern, A.; Senekowitsch-Schmidtke, R.; Essler, M. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS One, 2009, 4(5), e5715.
54. 213Bi labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis Eur. J. Nucl. Med. Mol. Imaging. 2012, in press.